Investigation of methicillin-resistant Staphylococcus aureus showing reduced vancomycin susceptibility isolated from a patient with infective endocarditis

International Journal of Antimicrobial Agents

Volumn 22, Issue 6, 2003, Pages 567-573

  Takayama, Yoko ^a   Hanaki, Hideaki ^a   Irinoda, Kazuhiko ^a   Kokubun, Hideya ^b   Yoshida, Kazunari ^a   Sunakawa, Keisuke ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Infective endocarditis; MRSA; Susceptibility MRSA; Therapeutic drug monitoring; Vancomycin

Indexed keywords

CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; PREDNISOLONE; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CASE REPORT; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCUBATION TIME; KIDNEY TRANSPLANTATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SIMULATION; TREATMENT FAILURE;

EID: 0345549443     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00263-2     Document Type: Article

References (33)

1. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:1997;135-136. Centers for Disease Control and Prevention.
2. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR Morb. Mortal Wkly Rep. 48:1999;1165-1167.
3. Sieradzki K., Roberts R.B., Haber S.W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New Engl. J. Med. 340:1999;517-523.
4. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. New Engl. J. Med. 340:1999;493-501.
5. Hanaki H., Labischinski H., Sasaki K., Kuwahara-Arai K., Inaba Y., Hiramatsu K. Mechanism of vancomycin resistance in MRSA strain Mu50. Jpn. J. Antibiot. 51:1998;237-247.
6. Hanaki H., Kuwahara-Arai K., Boyle-Vavra S., Daum R.S., Labischinski H., Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:1998;199-209.
7. Benn M., Hagelskjaer L.H., Tvede M. Infective endocarditis, 1984 through 1993: a clinical and microbiological survey. J. Int. Med. 242:1997;15-22.
8. Espersen F., Frimodt-Møller N. Staphylococcus aureus endocarditis: a review of 119 cases. Arch. Int. Med. 146:1986;1118-1121.
9. Gwynne-Jones D.P., Stott N.S. Community-acquired methicillin-resistant Staphylococcus aureus: a cause of musculoskeletal sepsis in children. J. Pediatr. Orthop. 19:1999;413-416.
10. Sanabria T.J., Alpert J.S., Goldberg R., Pape L.A., Cheeseman S.H. Increasing frequency of staphylococcal infective endocarditis: experience at a university hospital, 1981 through 1988. Arch. Int. Med. 150:1990;1305-1309.
11. Yoshiyama Y., Yazaki T., Wong P.C., Beauchamp D., Kanke M. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. J. Infect. Chemother. 7:2001;243-246.
12. Hanaki H., Inaba Y., Sasaki K., Hiramatsu K. A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (hetero-VRSA). Jpn. J. Antibiot. 51:1998;521-530.
13. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1670-1673.
14. National Committee for Clinical Laboratory Standards (NCCLS). Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17, no. 2. Approved standard M7-A4. Wayne, PA: NCCLS, 1997.
15. Hasegawa H. Evaluation of the dosing regimen of vancomycin for methicillin-resistant Staphylococcus aureus infections: in vitro experimental study on doses and infusion durations. Chemotherapy. 41:1993;329-338.
16. Sasaki S., Nishimura K., Yoshida I., Munekage T., Imamura N., Ito M. Study of an auto-simulation apparatus for evaluating bactericidal activity of antibiotics in human serum. Chemotherapy. 41:1993;1056-1063.
17. Ba B.B., Bernard A., Iliadis A., et al. New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin. J. Antimicrob. Chemother. 47:2001;223-227.
18. Kimura T., Kokubun H., Shimada S. Development of clinically oriented PK simulation program "Clin Kinetics-K" TDM Res. 17:(1):2000;30-36.
19. Krogstad D.J., Moellering R.C., Greenblatt D.J. Single-dose kinetics of intravenous vancomycin. J. Clin. Pharmacol. 41:1980;197-201.
20. Winter M.E. 18. Vancomycin. Koda-kimble M.A. Basic clinical pharmacokinetics. 3rd ed:1994;474-499 Applied Therapeutics, Inc, Vancouver, WA. Part II.
21. Yano H., Suetake M., Kuga A., et al. Pulsed-field gel electrophoresis analysis of nasopharyngeal flora in children attending a day care center. J. Clin. Microbiol. 38:2000;625-629.
22. May J., Shannon K., King A., French G. Glycopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother. 42:1998;189-197.
23. Ferraz V., Dusé A.G., Kassel M., Black A.D., Ito T., Hiramatsu K. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S. Afr. Med. J. 90:2000;1113.
24. Haraga I., Nomura S., Nagayama A. The effects of vancomycin and β-lactam antibiotics on vancomycin-resistant Staphylococcus aureus. New Engl. J. Med. 341:1999;1624-1625.
25. Kim M.N., Pai C.H., Woo J.H., Ryu J.S., Hiramatsu K. Vancomycin- intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38:2000;3879-3881.
26. Oliveira G.A., Dell'Aquila A.M., Masiero R.L., et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control. Hosp. Epidemiol. 22:2001;443-448.
27. Ploy M.C., Grélaud C., Martin C., de Lumley L., Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 351:1998;1212.
28. Wong S.S.Y., Ho P.L., Woo P.C.Y., Yuen K.Y. Bacteremia caused by Staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29:1999;760-767.
29. Wong S.S.Y., Ng T.K., Yam W.C., et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn. Microbiol. Infect. Dis. 36:2000;261-268.
30. Glycopeptide intermediate Staphylococcus aureus (GISA) death in Scotland. Eurosurveillance Wkly. 6:2002;51.
31. Hanaki H. A novel detection method of hetero-VRSA. Antibiot. Chemother. 15:1999;575-581.
32. Hanaki H., Hiramatsu K. Combination effects of teicoplanin and various antibiotics against hetero-VRSA and VRSA. J. J. A. Inf. D. 73:1999;1048-1053.
33. Utsui Y., Ishii C., Abe T., Kakuta M., Ohya S. Combination effect of teicoplanin and panipenem on highly resistant strains of MRSA. Jpn. J. Antibiot. 52:1999;268-277.